Q2 2026 Karyopharm Therapeutics Inc. Earnings Call Transcript
Key Points
- SENTRY trial demonstrated statistically significant, rapid, deep, and sustained spleen responses, with a nearly double SVR35 rate at week 24 for selinexor plus ruxolitinib versus ruxolitinib alone.
- Promising overall survival signal with a hazard ratio of 0.43, and a post hoc landmark analysis showing SVR35 at week 24 predicts overall survival, supporting SVR35 as a surrogate endpoint.
- FDA feedback indicates SVR35 appears to qualify as a reasonably likely surrogate endpoint for overall survival, enabling a planned sNDA submission under the Accelerated Approval Pathway.
- Established commercial hematology platform with existing relationships in community and academic settings, plus the KaryoForward patient support program, positions for a rapid and efficient launch if approved.
- Multiple myeloma franchise remains resilient with Q2 XPOVIO net product revenue of $30.8 million, providing a stable commercial foundation.
- SENTRY data published in the Journal of Clinical Oncology and presented at ASCO and EHA, generating strong interest and scientific engagement in the hematology community.
- Potential for up to $1 billion in peak annual US revenue in myelofibrosis, with no approved combination therapy in frontline setting.
- Phase 3 XPORT-EC-042 study in endometrial cancer failed to meet its primary endpoint, leading to a decision to reduce investment in that program.
- Cash position is tight, with $65.4 million in cash expected to fund operations only into September 2026, and a $15.8 million debt payment due on September 10, 2026, which could trigger a liquidity covenant breach.
- The company is actively evaluating financing opportunities and strategic alternatives, indicating potential dilution or restructuring risk.
- Accelerated approval is not guaranteed, and the confirmatory overall survival data from SENTRY will take years to mature, creating uncertainty for full approval.
- The sNDA submission is still pending, and the FDA's decision on priority review is unknown, which could delay potential approval beyond the first quarter of 2027.
- Net loss widened to $67 million in Q2 2026, partly due to non-cash mark-to-market adjustments, reflecting financial pressure.
- The company is reducing investment in endometrial cancer, which may limit future growth opportunities in that indication.
Good morning. My name is Anas, and I'll be your conference operator today. At this time, I would like to welcome everyone to Karyopharm's second-quarter 2026 financial results conference call. (Operator Instructions)
Please be advised that this call is being recorded at the company's request. I would now like to turn the conference over to Brandon Strong, Senior Vice President, Investor Relations.
Good morning, and thank you all for joining us on today's conference call to discuss Karyopharm's second quarter 2026 financial results and recent company progress. We issued a press release this morning detailing our financial results for the second quarter of 2026. This release, along with the slide presentation that we will reference during our call today, are available on our website.
For today's call, as shown on slide 2, I'm joined by Richard, Reshma, Sohanya, and Lori, who will review our second quarter financial results, provide an update on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
